secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001516551-25-000043
Event type: earnings
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience Q1 net loss $11.1M; nimacimab combo shows >30% weight loss in preclinical
--------------------------------------------------------------------------------

- Net loss for Q1 2025 was $11.1M ($2.2M non-cash share-based comp) vs $5.0M in Q1 2024.
- Cash and short-term investments total $59.2M; expected to fund operations through at least Q1 2027.
- Preclinical DIO model: nimacimab + tirzepatide achieved >30% weight loss; nimacimab alone 23.5% comparable to monlunabant and tirzepatide alone.
- In vitro data shows superior potency of peripherally restricted nimacimab vs small molecule monlunabant under pathological CB1 agonist levels.
- Top-line data from Phase 2a CBeyond study of nimacimab expected late Q3/early Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655125000043/0001516551-25-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655125000043/skye-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001516551-25-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer